Announcement • Feb 05
Singapore Paincare Holdings Limited to Report First Half, 2026 Results on Feb 13, 2026 Singapore Paincare Holdings Limited announced that they will report first half, 2026 results on Feb 13, 2026 Announcement • Dec 15
Singapore Paincare Holdings Limited, Annual General Meeting, Dec 30, 2025 Singapore Paincare Holdings Limited, Annual General Meeting, Dec 30, 2025, at 14:00 Singapore Standard Time. Location: seletar country club, 101 seletar club road, singapore 798273, Singapore Reported Earnings • Oct 30
Full year 2025 earnings released: S$0.024 loss per share (vs S$0.011 profit in FY 2024) Full year 2025 results: S$0.024 loss per share (down from S$0.011 profit in FY 2024). Revenue: S$27.1m (down 1.4% from FY 2024). Net loss: S$4.03m (down 305% from profit in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 68 percentage points per year, which is a significant difference in performance. New Risk • Sep 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (S$27.0m market cap, or US$21.0m). Announcement • May 29
Lee Mun Kam Bernard, Executive Chairman and Chief Executive Officer, and Loh Foo Keong Jeffrey, Executive Director and Chief Operating Officer of Singapore Paincare Holdings Limited, entered into an implementation agreement to acquire remaining 55.23% stake in Singapore Paincare Holdings Limited (Catalist:FRQ) from Sian Chay Medical Institution., and Jitendra Kumar Sen for SGD 15.1 million. Lee Mun Kam Bernard, Executive Chairman and Chief Executive Officer, and Loh Foo Keong Jeffrey, Executive Director and Chief Operating Officer of Singapore Paincare Holdings Limited, entered into an implementation agreement to acquire remaining 55.23% stake in Singapore Paincare Holdings Limited (Catalist:FRQ) from Sian Chay Medical Institution., and Jitendra Kumar Sen for SGD 15.1 million on May 28, 2025. As part of the acquisition, Lee Mun Kam Bernard and Loh Foo Keong Jeffrey through a special purpose vehicle Advance Bridge Healthcare Pte. Ltd will acquire the remaining 94.5 million shares at a price of SGD 0.16 per share. Sian Chay Medical Institution and Jitendra Kumar Sen has given an irrevocable undertaking to the Offeror in respect of 42.9 million Scheme Shares representing approximately 25.11% stake in Singapore Paincare Holdings Limited. Pursuant to the terms of the Implementation Agreement, subject to prior consultation with the Securities Industry Council of Singapore (“SIC”), in the event a Competing Offer is announced, the Offeror shall have the right at its sole discretion to elect to proceed by way of a voluntary conditional cash offer or a pre conditional voluntary cash offer. if the Scheme has not become effective by no later than six months from the Joint Announcement Date, either Party may immediately terminate the Implementation Agreement by notice in writing to the other Party.
The transaction is subject to SGX-ST’s Approval-In-Principle, Scheme Meeting for the approval of shareholders of Singapore Paincare Holdings Limited, Court Sanction and delisting of shares from the Catalist board of the SGX-ST. The Scheme is conditional upon the satisfaction by no later than six months from the Joint Announcement Date. The transaction has been approved the board of directors of Singapore Paincare Holdings Limited and Advance Bridge Healthcare Pte. Ltd.
Asian Corporate Advisors Pte. Ltd. acted as financial advisor to the directors of Singapore Paincare Holdings Limited. United Overseas Bank Limited acted as financial advisor to Lee Mun Kam Bernard and Loh Foo Keong Jeffrey. Reported Earnings • Feb 18
First half 2025 earnings released: EPS: S$0.003 (vs S$0.006 in 1H 2024) First half 2025 results: EPS: S$0.003 (down from S$0.006 in 1H 2024). Revenue: S$14.2m (up 5.6% from 1H 2024). Net income: S$453.0k (down 53% from 1H 2024). Profit margin: 3.2% (down from 7.2% in 1H 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings. New Risk • Jan 23
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: S$13.5m (US$9.96m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 11% per year over the past 5 years. Market cap is less than US$10m (S$13.5m market cap, or US$9.96m). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change). Reported Earnings • Oct 12
Full year 2024 earnings released: EPS: S$0.011 (vs S$0.004 loss in FY 2023) Full year 2024 results: EPS: S$0.011 (up from S$0.004 loss in FY 2023). Revenue: S$27.5m (up 23% from FY 2023). Net income: S$1.97m (up S$2.63m from FY 2023). Profit margin: 7.1% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Announcement • Sep 18
Singapore Paincare Holdings Limited Announces Changes to the Composition of the Board The Board of Directors of Singapore Paincare Holdings Limited announced the following changes with effect from 18 September 2024: the re-designation of Dr. Lee Mun Kam, Bernard (‘Dr. Lee’) as Executive Chairman of the Company. Dr. Lee will remain as Chief Executive Officer of the Company; and the re-designation of Ms. Lai Chin Yee (‘Ms. Lai’) as Lead Independent Director of the Company. Ms. Lai will also relinquish her role as Non-Executive Chairman. Ms. Lai will continue acting as Chairman of the Audit Committee (‘AC’) and Remuneration Committee (‘RC’) and Member of the Nominating Committee (‘NC’). Consequent to the above, the composition of the Board is as follows: Board of Directors: Dr. Lee Mun Kam, Bernard - Executive Chairman and Chief Executive Officer; Ms. Lai Chin Yee - Lead Independent Director; Dr. Loh Foo Keong, Jeffrey - Executive Director and Chief Operating Officer; Mr. Wong Yee Kong - Independent Non-Executive Director; Dr. Lim Kah Meng - Independent Non-Executive Director; The compositions of the AC, NC and RC remain unchanged. Reported Earnings • Aug 31
Full year 2024 earnings released: EPS: S$0.012 (vs S$0.003 loss in FY 2023) Full year 2024 results: EPS: S$0.012 (up from S$0.003 loss in FY 2023). Revenue: S$27.5m (up 23% from FY 2023). Net income: S$1.97m (up S$2.47m from FY 2023). Profit margin: 7.1% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Announcement • Aug 21
Singapore Paincare Holdings Limited Appoints Isaac Peh Lin Siah as Financial Controller, Effective August 22, 2024 Singapore Paincare Holdings Limited announced the appointment of Isaac Peh Lin Siah as Financial Controller. Role And Responsibilities Overseeing the accounting, finance and tax functions of the Group. Working Experience March 2021 to May 2024 - BR Metals Pte. Ltd., Group Financial Controller May 2020 to March 2021 - Koda Ltd, Group Financial Controller March 2019 to April 2020 - Isetan Singapore Ltd, Financial Controller December 2013 to February 2019 - Shanghai Turbo Enterprises Ltd, Financial Controller. Professional Qualifications Fellow Chartered Public Accountant CPA Australia Chartered Public Accountant CPA Australia CIMA - The Chartered Institute of Management Accountants ACCA - The Association of Chartered Certified Accountants Bachelor of Arts, National University of Singapore. Date of appointment is August 22, 2024. New Risk • Jun 28
New minor risk - Dividend sustainability The dividend is not well covered by earnings. The company is paying a dividend despite being loss-making. Dividend yield: 2.7% This is considered a minor risk. Companies that pay out too much of their earnings are at risk of having to reduce or cut their dividend in future. If earnings growth slows or earnings fall, then there may not be enough earnings to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. However, this risk is mitigated by the fact the dividend is covered by cash flows. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 10% per year over the past 5 years. Minor Risks Paying a dividend despite being loss-making. Market cap is less than US$100m (S$23.4m market cap, or US$17.2m). Buy Or Sell Opportunity • Jun 10
Now 23% undervalued The stock has been flat over the last 90 days, currently trading at S$0.15. The fair value is estimated to be S$0.20, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Meanwhile, the company became loss making. Board Change • Apr 30
High number of new directors Independent Non-Executive Director Andrew Wong was the last director to join the board, commencing their role in 2024. Announcement • Apr 20
Singapore Paincare Holdings Limited Announces the Appointment of Soh Chiong Siong as Financial Controller, Effective April 22, 2024 Singapore Paincare Holdings Limited announced the appointment of Soh Chiong Siong as Financial Controller, effective April 22, 2024. The Board of Directors having considered the recommendation of the Nominating Committee and reviewed the qualification and experience of Mr. Soh Chiong Siong ("Mr. Soh"), is of the view that Mr. Soh has the requisite experience and capabilities to assume the duties and responsibilities as the Financial Controller of the Company. Working Experience: August 2019 to April 2024 - Canopy Pte. Ltd., Head of Finance December 2016 to March 2017 - AEP Investment Management Pte. Ltd., Chief Financial Officer August 2015 to May 2016 - The American Club, Director of Finance May 2015 to August 2015 - ICP Ltd., Chief Financial Officer May 2012 to November 2014 - Frasers Centrepoint Limited, Senior Manager, Special Project. He holds Master of Science in Professional Accountancy from University of London. Board Change • Apr 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Non-Executive Director Kah Meng Lim was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Buy Or Sell Opportunity • Mar 01
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 16% to S$0.16. The fair value is estimated to be S$0.21, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Meanwhile, the company became loss making. Announcement • Jan 29
Singapore Paincare Holdings Limited Announces Yap Beng Tat, Richard Resigns as Independent Non-Executive Director Singapore Paincare Holdings Limited announced that Mr. Yap Beng Tat, Richard, ("Mr. Yap") has resigned as Independent Non-Executive Director of the Company to pursue his personal interests. Role And Responsibilities: Independent Non-Executive Director. Job Title: Chairman of Nominating Committee and member of Audit Committee and Remuneration Committee. Announcement • Jan 19
Singapore Paincare Holdings Limited Announces Resignation of Lim Mong Ai, Karen as Financial Controller Singapore Paincare Holdings Limited announced that Ms. Lim Mong Ai, Karen ("Ms. Karen") has resigned as Financial Controller of the company to pursue other career opportunities. Ms. Karen is responsible for overseeing the Group's finance and accounting matters. Buying Opportunity • Jan 05
Now 20% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be S$0.21, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Meanwhile, the company became loss making. Announcement • Oct 21
Singapore Paincare Holdings Limited Proposes Final Dividend (Tax Exempt One-Tier) for the Financial Year Ended 30 June 2023, Payable on November 17, 2023 Singapore Paincare Holdings Limited proposed final dividend being obtained at the forthcoming Annual General Meeting of the Company to be held on 27 October 2023, the Share Transfer Books and Register of Members of the Company will be closed at 5.00 p.m. on 8 November 2023 for the purpose of determining shareholders' entitlements to the proposed final dividend (tax-exempt one-tier) of 0.35 Singapore cents (SGD 0.0035) per ordinary share ("Share") for the financial year ended 30 June 2023 (the "Final Dividend"). Shareholders (being depositors) whose securities accounts with The Central Depository (Pte) Limited are credited with the Shares as at 5.00 p.m. on 8 November 2023 will be entitled to the proposed Final Dividend. The proposed Final Dividend, if approved at the forthcoming Annual General Meeting of the Company to be held on 27 October 2023, will be paid on 17 November 2023. Reported Earnings • Oct 13
Full year 2023 earnings released: S$0.003 loss per share (vs S$0.022 profit in FY 2022) Full year 2023 results: S$0.003 loss per share (down from S$0.022 profit in FY 2022). Revenue: S$22.4m (up 17% from FY 2022). Net loss: S$502.0k (down 113% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Announcement • Oct 13
Singapore Paincare Holdings Limited Proposes Final Dividend (Tax Exempt One-Tier) for the Financial Year Ended 30 June 2023 Singapore Paincare Holdings Limited at its AGM to be held on 27 October 2023, to consider the declaration of final dividend (tax exempt one-tier) of SGD 0.0035 per ordinary share for the financial year ended 30 June 2023 (Fiscal year 2022: SGD 0.012 per ordinary share). Announcement • Oct 12
Singapore Paincare Holdings Limited, Annual General Meeting, Oct 27, 2023 Singapore Paincare Holdings Limited, Annual General Meeting, Oct 27, 2023, at 14:00 Singapore Standard Time. Location: Seletar Country Club, 101 Seletar Club Road, Singapore 798273 Singapore Singapore Agenda: To receive and adopt the Directors' Statement and the Audited Financial Statements of the Company for the financial year ended 30 June 2023 together with the Independent Auditors's Report thereon; to declare a final dividend (tax-exempt one-tier) of SGD 0.0035 per ordinary share for the financial year ended 30 June 2023; to approve the payment of Directors's Fees of SGD 76,452 for the financial year ended 30 June 2023; to consider reelection of directors; to consider the reappointment of BDO LLP as the Independent Auditors of the Company and to authorize the Directors to fix their remuneration; and to consider other matters. Reported Earnings • Aug 30
Full year 2023 earnings released: S$0.003 loss per share (vs S$0.022 profit in FY 2022) Full year 2023 results: S$0.003 loss per share (down from S$0.022 profit in FY 2022). Revenue: S$22.4m (up 17% from FY 2022). Net loss: S$502.0k (down 113% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. New Risk • Aug 19
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (S$33.7m market cap, or US$24.8m). Announcement • Jul 01
Singapore Paincare Holdings Limited Appoints Lim Mong Ai, Karen as Financial Controller, Effective July 1, 2023 Singapore Paincare Holdings Limited announced that Board of Directors (the "Board") having considered the recommendation of the Nominating Committee and reviewed the qualification and experience of Ms. Lim Mong Ai, Karen ("Ms. Lim"), is of the view that Ms. Lim has the requisite experience and capabilities to assume the duties and responsibilities as the Financial Controller of the Company. Role And Responsibilities: Overseeing the accounting, finance and tax functions of the Group. Working Experience: October 2011 - June 2023 Global Palm Resources Holdings Limited Group Financial Accounting Manager. Professional Qualifications: Bachelor of Business (Accountancy). Appointment date is July 1, 2023. Reported Earnings • Feb 15
First half 2023 earnings released First half 2023 results: Revenue: S$11.1m (up 31% from 1H 2022). Net income: S$803.0k (down 65% from 1H 2022). Profit margin: 7.2% (down from 27% in 1H 2022). Announcement • Jan 21
Singapore Paincare Holdings Limited Appoints Lim Kah Meng as Chairman of the Remuneration Committee and A Member of the Audit Committee and the Nominating Committee The board of directors of Singapore Paincare Holdings Limited announced the appointment of Dr. Lim Kah Meng (Dr. Lim), who is currently an independent non-executive director of the company, as chairman of the remuneration committee and a member of the audit committee and the nominating committee with effect from 20 January 2023. Consequently, the composition of the respective board committees are as follows: Remuneration Committee: Dr. Lim Kah Meng, Chairman; Mr. Yap Beng Tat, Richard (Ye Mingda, Richard); Ms. Lai Chin Yee. Audit Committee: Ms. Lai Chin Yee, Chairman, Mr. Yap Beng Tat, Richard (Ye Mingda, Richard), Dr. Lim Kah Meng. Nominating Committee: Mr. Yap Beng Tat, Richard (Ye Mingda, Richard) Chairman, Ms. Lai Chin Yee, Dr. Lim Kah Meng. Upcoming Dividend • Oct 31
Upcoming dividend of S$0.012 per share Eligible shareholders must have bought the stock before 07 November 2022. Payment date: 17 November 2022. Payout ratio is a comfortable 55% and this is well supported by cash flows. Trailing yield: 6.1%. Lower than top quartile of Singaporean dividend payers (6.8%). Higher than average of industry peers (2.2%). Announcement • Oct 28
Singapore Paincare Holdings Limited Approves Final Dividend (Tax-Exempt One-Tier) for the Financial Year Ended 30 June 2022 Singapore Paincare Holdings Limited approved final dividend (tax-exempt one-tier) of SGD 0.012 per ordinary share for the financial year ended 30 June 2022 at its annual general meeting held on October 27, 2022. Reported Earnings • Oct 10
Full year 2022 earnings released: EPS: S$0.022 (vs S$0.013 in FY 2021) Full year 2022 results: EPS: S$0.022 (up from S$0.013 in FY 2021). Revenue: S$19.2m (up 69% from FY 2021). Net income: S$3.90m (up 77% from FY 2021). Profit margin: 20% (up from 19% in FY 2021). The increase in margin was driven by higher revenue. Reported Earnings • Aug 24
Full year 2022 earnings released: EPS: S$0.022 (vs S$0.013 in FY 2021) Full year 2022 results: EPS: S$0.022 (up from S$0.013 in FY 2021). Revenue: S$19.9m (up 75% from FY 2021). Net income: S$3.90m (up 77% from FY 2021). Profit margin: 20% (in line with FY 2021). Announcement • Aug 24
Singapore Paincare Holdings Limited Recommends Final Dividend The directors of Singapore Paincare Holdings Limited recommending a final dividend of 1.20 cent per ordinary share (one tier tax exempt), which will be subjected to shareholders' approval at the forthcoming annual general meeting in October 2022. Announcement • Jul 01
Singapore Paincare Holdings Limited Announces Promotion of Leow Yong Kin from Financial Controller to Chief Financial Officer Singapore Paincare Holdings Limited announced promotion of Leow Yong Kin from Financial Controller to Chief Financial Officer. Working Experience: September 2021 - 30 June 2022 Singapore Paincare Holdings Limited Financial Controller April 2017 - Present AccountsPro Consulting Services Pte Limited Business Consultant February 2012 - March 2017 China Great Land Holdings Limited Chief Financial Officer (July 2014 - March 2017) Consultant (November 2013 - June 2014) Financial Controller (February 2012 - October 2013). Professional Qualifications: Association of Chartered Certified Accountants. Board Change • Jun 14
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Executive Director & CEO Bernard Lee is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Apr 28
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Executive Director & CEO Bernard Lee is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Feb 16
First half 2022 earnings: Revenues and EPS in line with analyst expectations First half 2022 results: EPS: S$0.013 (up from S$0.004 in 1H 2021). Revenue: S$8.48m (up 65% from 1H 2021). Net income: S$2.27m (up 236% from 1H 2021). Profit margin: 27% (up from 13% in 1H 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Reported Earnings • Oct 05
Full year 2021 earnings released: EPS S$0.013 (vs S$0.031 in FY 2020) The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2021 results: Revenue: S$11.4m (up 14% from FY 2020). Net income: S$2.20m (up 17% from FY 2020). Profit margin: 19% (in line with FY 2020). Reported Earnings • Aug 22
Full year 2021 earnings released: EPS S$0.013 (vs S$0.031 in FY 2020) The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2021 results: Revenue: S$11.6m (up 17% from FY 2020). Net income: S$2.20m (up 17% from FY 2020). Profit margin: 19% (in line with FY 2020). Announcement • Mar 06
Singapore Paincare Holdings Limited Appoints Dr. Lim Kah Meng as Independent Non-Executive Director Singapore Paincare Holdings Limited appointed Dr. Lim Kah Meng as Independent Non-Executive Director of the Company, with effect from March 05, 2021. September 2001 to Current - Gene Oasis Pte. Ltd., Chief Executive Officer September 2017 to Current - NGF BioEnterprise Pte. Ltd., Managing Director September 2017 to Current - FEGO Biotech Pte. Ltd., Managing Director July 2015 to Current - GeneOasis Bioscientific Pte. Ltd., Managing Director January 2018 to Current - Alphacel Singapore Pte Ltd, Chief Science Advisor June 2012 to Current - Extend International, Chief Science Officer January 2014 to December 2016 - Institute of Advanced Technologies (Wuqing) of Tianjin University, Adjunct Associate Professor, Division of Biological Engineering March 2012 to March 2013 - Nanyang Technological University, Adjunct Assistant Professor, School of Chemical and Biomedical Engineering July 2012 to January 2014 (Dormant) - South East Asia Bird's Nest Chamber of Commerce, President January 2010 to January 2012 - Riway (Singapore) Pte. Ltd., Chief Science Officer. Reported Earnings • Feb 07
First half 2021 earnings released: EPS S$0.004 (vs S$0.01 in 1H 2020) The company reported a poor first half result with weaker earnings and profit margins, although revenues were flat. First half 2021 results: Revenue: S$5.15m (flat on 1H 2020). Net income: S$674.9k (down 41% from 1H 2020). Profit margin: 13% (down from 22% in 1H 2020). Announcement • Dec 04
Singapore Paincare Holdings Limited (Catalist:FRQ) completed the acquisition of 40% stake in KCS Anaesthesia Services Pte. Ltd from Kong Chee Sang. Singapore Paincare Holdings Limited (Catalist:FRQ) agreed to acquire 40% stake in KCS Anaesthesia Services Pte. Ltd. from Kong Chee Sang for SGD 2.4 million on November 30, 2020. Under the terms of consideration, SGD 2.4 million will be payable in cash by way of wire transfer of immediately available funds to an account designated by Kong Chee Seng. The purchase price for the sale shares shall be fully funded through the net proceeds from the Singapore Paincare Holdings's initial public offer in July 2020. For the year ended on February 29, 2020, KCS Anaesthesia Services reported net asset value of SGD 0.500782 million and profit after tax of SGD 1.071901 million. The deal is subject to obtained the necessary approvals from the board, shareholders and or relevant authorities (where applicable) for the sale and purchase of the sale shares. The SPA completion shall take place on or before December 2, 2020, or such other date as the Singapore Paincare Holdings Limited and Kong Chee Seng may mutually agree in writing.
Singapore Paincare Holdings Limited (Catalist:FRQ) completed the acquisition of 40% stake in KCS Anaesthesia Services Pte. Ltd. from Kong Chee Sang on December 2, 2020. Is New 90 Day High Low • Dec 04
New 90-day high: S$0.23 The company is up 16% from its price of S$0.20 on 04 September 2020. The Singaporean market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 3.0% over the same period. Announcement • Dec 01
Singapore Paincare Holdings Limited (Catalist:FRQ) agreed to acquire 40% stake in Kong Chee Seng fro SGD 2.4 million. Singapore Paincare Holdings Limited (Catalist:FRQ) agreed to acquire 40% stake in Kong Chee Seng fro SGD 2.4 million on November 30, 2020. Under the terms of consideration, SGD 2.4 million will be payable in cash by way of wire transfer of immediately available funds to an account designated by Kong Chee Seng. The purchase price for the sale shares shall be fully funded through the net proceeds from the Singapore Paincare Holdings's initial public offer in July 2020. The deal is subject to obtained the necessary approvals from the board, shareholders and or relevant authorities (where applicable) for the sale and purchase of the sale shares. The SPA completion shall take place on or before December 2, 2020, or such other date as the Singapore Paincare Holdings Limited and Kong Chee Seng may mutually agree in writing. Announcement • Nov 28
Singapore Paincare Holdings Limited has completed a Follow-on Equity Offering in the amount of SGD 3.96 million. Singapore Paincare Holdings Limited has completed a Follow-on Equity Offering in the amount of SGD 3.96 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 18,000,000
Price\Range: SGD 0.22
Transaction Features: Subsequent Direct Listing Reported Earnings • Oct 04
Full year earnings released - EPS S$0.031 Over the last 12 months the company has reported total profits of S$1.88m, up 49% from the prior year. Total revenue was S$9.96m over the last 12 months, up 155% from the prior year. Profit margins were 19%, which is lower than the 32% margin from last year. The decrease in margin was driven by higher expenses. Announcement • Jul 31
Singapore Paincare Holdings Limited has completed an IPO in the amount of SGD 5.33412 million. Singapore Paincare Holdings Limited has completed an IPO in the amount of SGD 5.33412 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 24,246,000
Price\Range: SGD 0.22
Discount Per Security: SGD 0.0088
Transaction Features: Direct Listing; Sponsor Backed Offering